Renin aldosteron mechanism
Reading File
Searching Images
renin angiotensin aldosterone system RAAS mechanism diagram
Finding Sources
Searching Images
renin angiotensin aldosterone system kidney blood pressure regulation
Reading File
Finding Sources
Reading File
Reading File
Reading File
Loading Image
Reading File
I now have everything needed for a thorough answer. Here is the full explanation:
Renin-Angiotensin-Aldosterone System (RAAS)
Overview
The RAAS is a hormonal cascade that regulates arterial blood pressure (Pa), extracellular fluid (ECF) volume, and electrolyte balance. It is activated primarily by a fall in renal perfusion pressure and works over hours to days (much slower than the baroreceptor reflex because it is hormonally mediated).
Step-by-Step Cascade
Step 1 - Renin Release
Three stimuli trigger renin secretion from the juxtaglomerular (JG) cells of the afferent arteriole:
| Stimulus | Sensor |
|---|---|
| Decreased renal perfusion pressure | Baroreceptors (mechanoreceptors) in granular cells |
| Decreased Na⁺/Cl⁻ at distal tubule | Macula densa cells |
| Sympathetic activation | β1-adrenergic receptors on JG cells |
Renin is a 36-kDa aspartyl protease (gene: REN, chromosome 1q32.1). β1-blockers (e.g., propranolol) inhibit renin release; β1-agonists (e.g., isoproterenol) stimulate it.
Step 2 - Angiotensin I Formation
Renin cleaves the N-terminal 10 amino acids from angiotensinogen (a 485-amino-acid α-globulin produced by the liver, gene: AGT, chromosome 1q42.2), producing angiotensin I - a hormonally inert decapeptide. Angiotensinogen is normally in excess, so angiotensin I production is rate-limited by renin concentration.
Step 3 - Angiotensin II Formation
Angiotensin-converting enzyme (ACE) - a zinc-dependent dicarboxypeptidase (gene: ACE, chromosome 17q23.3) - removes the two C-terminal residues (histidine and leucine) from angiotensin I, producing the active octapeptide angiotensin II. ACE is found primarily in pulmonary endothelium but is also widely distributed in endothelial and epithelial tissues throughout the body.
ACE inhibitors (e.g., captopril, enalapril) block this step and all downstream effects.
Step 4 - Angiotensin II Actions
Angiotensin II acts via AT1 receptors (Gq-coupled) in multiple organs:
| Target | Effect |
|---|---|
| Adrenal zona glomerulosa | Stimulates aldosterone synthesis and secretion |
| Renal proximal tubule | Stimulates Na⁺-H⁺ exchange → Na⁺ and HCO₃⁻ reabsorption (direct, aldosterone-independent) |
| Arterioles | Vasoconstriction via IP3/Ca²⁺ signaling → increased total peripheral resistance → increased Pa |
| Hypothalamus | Increases thirst and water intake |
| Posterior pituitary | Stimulates ADH (vasopressin) release → water reabsorption in collecting ducts |
| Adrenal medulla | Increases norepinephrine and epinephrine release |
| Heart/kidney (local RAAS) | Promotes cardiac hypertrophy, fibrosis, and tubular Na⁺ retention via local AT1 receptors |
AT1 receptor blockers (ARBs; e.g., losartan, valsartan) block all of these effects at the tissue level.
Step 5 - Aldosterone Release and Action
Angiotensin II binding to AT1 receptors on zona glomerulosa cells stimulates aldosterone synthesis. Aldosterone then acts on the principal cells of the distal tubule and collecting duct to:
- Increase Na⁺ reabsorption (via ENaC channels and Na⁺/K⁺-ATPase)
- Increase K⁺ and H⁺ secretion
This increases total body Na⁺, ECF volume, blood volume, venous return, cardiac output (Frank-Starling), and ultimately Pa. These genomic actions require gene transcription and new protein synthesis, explaining the slow onset (hours to days).
Additional Stimuli for Aldosterone (Independent of Renin)
- Hyperkalemia - directly stimulates zona glomerulosa cells via a calcium-mediated signaling pathway
- ACTH - causes a transient aldosterone rise; effect wanes even if ACTH remains elevated (escape phenomenon)
- Minor regulators: serotonin, local chromaffin/endothelial/immune cell factors
Negative Feedback
- Restoration of renal perfusion pressure and increased Na⁺ delivery to the macula densa suppresses further renin release
- There is evidence (not conclusively proven) that angiotensin II may inhibit renin secretion directly via AT1 receptors on JG cells ("short-loop" feedback)
- Aldosterone-mediated Na⁺ and volume retention reduces the original hypoperfusion stimulus
Key Pharmacological Targets
| Drug Class | Site of Action | Example |
|---|---|---|
| ACE inhibitors | Block ACE (Ang I → Ang II) | Captopril, Enalapril |
| ARBs | Block AT1 receptor | Losartan, Valsartan |
| Direct renin inhibitors | Block renin | Aliskiren |
| Aldosterone antagonists | Block mineralocorticoid receptor | Spironolactone, Eplerenone |
| β1-blockers | Reduce renin release | Propranolol, Metoprolol |
Clinical Importance
- Heart failure: RAAS activation is proportional to cardiac dysfunction severity. Initially compensatory (maintains perfusion), but chronic activation causes maladaptive myocardial remodeling, renal vasoconstriction, and progressive Na⁺ retention. RAAS inhibitors are foundational HF therapy.
- Primary hyperaldosteronism (Conn's syndrome): Autonomous aldosterone production independent of renin/angiotensin II (low renin, high aldosterone).
- Secondary hyperaldosteronism: High renin driving high aldosterone - seen in renal artery stenosis, heart failure, cirrhosis, nephrotic syndrome.
- Glucocorticoid-remediable aldosteronism (GRA): Autosomal dominant disorder where a hybrid 11β-hydroxylase/aldosterone synthase gene makes aldosterone ACTH-sensitive; corrected by glucocorticoid administration.
Sources: Costanzo Physiology 7th Ed., p. 680-700; Tietz Textbook of Laboratory Medicine 7th Ed., p. 2271-2272; Ganong's Review of Medical Physiology 26th Ed.; Brenner and Rector's The Kidney.
Pcod diagnosis treatment and new updates
Reading File
Finding Sources
Searching PubMed
polycystic ovary syndrome diagnosis treatment guidelines
Searching the Web
PCOS PCOD new updates 2024 2025 diagnosis treatment guidelines
Finding Sources
Reading Article
PMID: 37580861
Reading Web Page
https://www.ccjm.org/content/93/3/176
Reading File
Reading File
Searching Images
polycystic ovary syndrome ultrasound follicles hyperandrogenism
Loading Image
Finding Sources
Finding Sources
Reading File
Searching PubMed
GLP-1 receptor agonist PCOS treatment semaglutide
I now have comprehensive material from textbooks, the 2023 international guideline, and the latest PubMed evidence. Here is the full answer:
PCOS / PCOD - Diagnosis, Treatment & New Updates (2023-2025)
Note on terminology: PCOD (Polycystic Ovarian Disease) and PCOS (Polycystic Ovary Syndrome) are used interchangeably in clinical practice. PCOS is the internationally preferred term. The 2023 International Evidence-Based Guideline (Teede et al., PMID 37580861) is the most current authoritative reference, covering 196 countries.
1. What Is PCOS?
PCOS is the most common endocrine disorder in women of reproductive age, affecting 10-13% of women globally. It is a heterogeneous, lifelong syndrome arising from an interplay of genetic factors, insulin resistance, androgen excess, and proinflammatory changes. It causes ovulatory dysfunction, hyperandrogenism, and long-term cardiometabolic risk.
2. Diagnosis
Diagnostic Criteria - Three Systems
The Rotterdam 2003 criteria (most widely used) require 2 of 3:
| Feature | Definition |
|---|---|
| Oligo/anovulation | Cycle < 21 days or > 35 days, or < 8 cycles/year (in women ≥3 years post-menarche) |
| Clinical hyperandrogenism | Acne, hirsutism, androgenic alopecia |
| Biochemical hyperandrogenism | Elevated free/total testosterone, DHEAS, androstenedione |
| Polycystic ovaries on US | Ovarian volume > 10 mL and/or ≥ 12 follicles < 9 mm in at least one ovary |
Other conditions must be excluded first: hypothyroidism, hyperprolactinemia, non-classical congenital adrenal hyperplasia (CAH), androgen-secreting tumors, Cushing syndrome, and pregnancy. LH:FSH ratio and hyperinsulinemia are NOT required for diagnosis.
NEW (2023 Guideline Update): Anti-Müllerian Hormone (AMH)
- AMH is now included as an alternative to ultrasound in adults only - elevated AMH reflects increased follicle number and is a useful biomarker
- AMH should be interpreted alongside clinical and biochemical findings - it cannot diagnose PCOS alone
- AMH is NOT recommended for diagnosis in adolescents (no universal cutoff; levels affected by age, BMI, OCP use, and prior ovarian surgery)
- The guideline recommends a simplified, sequential diagnostic algorithm:
Step 1: Assess menstrual irregularity + clinical hyperandrogenism
→ If BOTH present: PCOS diagnosed (no further testing needed)
Step 2: If only one feature:
→ Add biochemical tests (free testosterone, DHEAS)
→ In adults: pelvic USS or AMH measurement
→ If either adds a second criterion: PCOS diagnosed
Step 3: Exclude other causes at all stages
Diagnosis in Special Populations
| Population | Key Points |
|---|---|
| Adolescents | Both irregular cycles AND hyperandrogenism required (USS/AMH not used); anovulation is physiologic for 2 years post-menarche |
| Perimenopausal | Difficult to diagnose; prior history of PCOS most helpful |
| Lean women | Still at risk for insulin resistance and cardiometabolic disease - screen regardless of BMI |
3. Comorbidity Screening (Mandatory at Diagnosis)
| Comorbidity | Test |
|---|---|
| Insulin resistance / Type 2 DM | 75-g OGTT, HbA1c, fasting glucose |
| Dyslipidemia | Fasting lipid profile |
| Endometrial hyperplasia | Endometrial biopsy if prolonged amenorrhea |
| Cardiovascular risk | Blood pressure, BMI, waist circumference |
| Sleep apnea | Questionnaire (Berlin/Epworth) |
| Anxiety, depression, eating disorders | Validated psychological screening tools |
| Pregnancy complications | Gestational diabetes, preeclampsia, preterm birth risk counseling |
The 2023 guideline significantly strengthens recognition of cardiovascular risk in PCOS. A 2024 meta-analysis (PMID 39119982, JAHA) confirmed elevated clinical CVD risk even in non-obese young women with PCOS.
4. Treatment
Treatment is individualized based on the patient's main concern (irregular cycles, hyperandrogenism, fertility, weight, or metabolic risk).
First-Line for ALL patients: Lifestyle Modification
- Weight loss of even 5% improves insulin sensitivity, restores ovulation, and reduces androgen levels
- Caloric deficit of 500 kcal/day + regular physical activity
- A 2024 systematic review (PMID 39445724) confirmed that physical activity improves androgen levels, menstrual regularity, and quality of life in PCOS independently of weight loss
- Any healthy diet pattern (Mediterranean, low-GI, low-carb) is acceptable; no single diet is superior
Treatment by Specific Goal
A. Menstrual Irregularity + Endometrial Protection
| Drug | Mechanism | Notes |
|---|---|---|
| Combined OCP (COCP) | Suppresses LH, increases SHBG, opposes estrogen | First-line for cycle regulation; also treats hyperandrogenism |
| Cyclic progestin | Induces withdrawal bleed | Medroxyprogesterone acetate 10 mg x 10 days; at least 4x/year to prevent endometrial hyperplasia |
| Metformin | Reduces insulin resistance, lowers androgens | Also improves cycle regularity; especially useful in metabolic phenotype |
B. Hyperandrogenism (Acne, Hirsutism, Hair Loss)
| Drug | Use |
|---|---|
| COCP | First-line; lowers free androgens by raising SHBG |
| Spironolactone | Androgen receptor blocker; add-on for resistant hirsutism; needs contraception (teratogenic) |
| Flutamide | Anti-androgen; limited by hepatotoxicity risk |
| Finasteride | 5α-reductase inhibitor for androgenic alopecia |
| Eflornithine cream | Topical for facial hirsutism |
| Laser/electrolysis | For cosmetic hair removal |
| Metformin | Modest anti-androgen effect via insulin lowering |
C. Fertility / Ovulation Induction
| Option | Notes |
|---|---|
| Weight loss (first) | 5% weight loss can restore spontaneous ovulation; improves treatment response |
| Letrozole (aromatase inhibitor) | Now preferred first-line over clomiphene - higher live birth rates, lower multiple pregnancy risk |
| Clomiphene citrate | Blocks hypothalamic estrogen receptors → increases GnRH → FSH surge; 60-85% ovulation rate, 15-20% pregnancy per cycle, 50% pregnant by 6 months |
| Metformin + letrozole/clomiphene | Combination improves outcomes in insulin-resistant PCOS |
| Gonadotropins (FSH injections) | For clomiphene/letrozole failure; risk of OHSS |
| Laparoscopic ovarian drilling (LOD) | Surgical option for gonadotropin-resistant cases; reduces androgen-secreting stroma |
| IVF | Last resort; PCOS patients at high OHSS risk - GnRH antagonist + freeze-all protocol preferred |
D. Metabolic / Weight Management
| Drug | Notes |
|---|---|
| Metformin | Reduces insulin resistance; first-line metabolic agent; also mildly improves cycles and androgens |
| GLP-1 receptor agonists (liraglutide, semaglutide) | ⭐ Major new update - see below |
| Inositol (myo-inositol + D-chiro-inositol) | Insulin sensitizer; improving evidence; used as supplement |
5. New Updates (2023-2025)
⭐ GLP-1 Receptor Agonists in PCOS
This is the most important recent pharmacological development:
- A 2025 meta-analysis (PMID 40360648) of RCTs found GLP-1 RAs significantly reduced BMI, waist circumference, fasting insulin, HOMA-IR, testosterone, and LH:FSH ratio in women with PCOS
- A 2025 meta-analysis (PMID 39881036) showed GLP-1 RA + metformin combination was superior to metformin alone for weight, insulin resistance, and androgen levels
- The 2023 international guideline explicitly recommends GLP-1 RAs (especially liraglutide) for obesity management in PCOS
- Semaglutide trials in PCOS are ongoing; current data is primarily from liraglutide and exenatide
- These agents do NOT replace standard ovulation-induction therapy but are valuable adjuncts in obese/insulin-resistant phenotypes
⭐ AMH as a Diagnostic Tool (2023 Guideline)
- AMH incorporated as an alternative to pelvic USS in adult women (see diagnosis section above)
- Simplifies diagnosis, especially for patients for whom USS is impractical
⭐ Cardiovascular Risk Recognition
- The 2023 guideline update formally elevated CVD screening as a mandatory component of PCOS assessment
- Even non-obese, lean women with PCOS have elevated long-term CVD risk
- Lipid, BP, and glucose screening should be performed regardless of BMI
⭐ Name Change Proposal (Emerging)
- Some endocrinologists have proposed renaming PCOS to "Polyendocrine Metabolic Ovarian Syndrome (PMOS)" to better reflect its systemic, metabolic nature and reduce stigma associated with "polycystic" - this is not yet formally adopted
⭐ Psychological Health
- The 2023 guideline mandates screening for anxiety, depression, disordered eating, and body image issues in ALL women with PCOS - previously underemphasized
- PCOS carries a very high prevalence of psychological comorbidities
6. Quick Reference Summary
DIAGNOSIS (Rotterdam - 2 of 3):
Oligo/anovulation + Hyperandrogenism + Polycystic ovaries (USS or AMH in adults)
↳ Exclude: hypothyroid, hyperprolactinemia, CAH, androgen tumors, Cushing's
TREATMENT:
All → Lifestyle modification (weight loss, exercise, diet)
Cycles → COCP or cyclic progestin
Hyperandrogenism → COCP ± spironolactone
Fertility → Letrozole (1st line) → Clomiphene → Gonadotropins → IVF
Metabolic → Metformin ± GLP-1 RA (new)
Screen → OGTT, lipids, BP, mood, endometrium
Sources: Berek & Novak's Gynecology; Textbook of Family Medicine 9e; Teede et al., 2023 International Evidence-Based PCOS Guideline (PMID 37580861); GLP-1 RA meta-analysis 2025 (PMID 40360648); CVD risk update 2024 (PMID 39119982); Cleveland Clinic Journal of Medicine 2025 update.
New name for pcos
Searching the Web
PCOS new name rename 2024 2025 proposal official
Searching PubMed
polycystic ovary syndrome renaming nomenclature
Reading Web Page
https://www.sciencedirect.com/science/article/pii/S014067362…
This is now confirmed and official. Here is the complete picture:
PCOS Has a New Name: PMOS
The Official Change
On May 12, 2026, polycystic ovary syndrome (PCOS) was formally and officially renamed to:
Polyendocrine Metabolic Ovarian Syndrome (PMOS)
This was announced via a landmark paper published in The Lancet (June 2026) by lead author Prof. Helena J. Teede and the Global Name Change Consortium. It is not a proposal - it is an internationally ratified name change, backed by 56 leading academic, clinical, and patient organisations worldwide, including the Endocrine Society and the International Androgen Excess and PCOS Society.
Why Was the Name Changed?
The old name "Polycystic Ovary Syndrome" had multiple serious problems:
| Problem with "PCOS" | Explanation |
|---|---|
| Cysts don't exist | There are no true ovarian cysts - the "polycystic" appearance on ultrasound is multiple small follicles, not cysts. The name caused widespread patient and clinician confusion |
| It's not just about the ovaries | PCOS affects metabolism, hormones, cardiovascular health, mental health, skin, and weight - reducing it to "ovarian" grossly understates the disease |
| Stigma and misunderstanding | Patients often thought they had ovarian cysts and felt dismissed; the name contributed to delayed diagnosis and fragmented care |
| Research and policy gaps | The name framed it as a reproductive/gynaecological condition, limiting research funding and policy attention for its systemic metabolic aspects |
How Was the New Name Chosen?
The process was rigorous and unprecedented in scale:
- 14,360 people with PCOS (patients) and multidisciplinary health professionals from all world regions were surveyed iteratively
- Methods included modified Delphi, nominal group workshops, marketing analyses, and implementation feasibility assessments
- Governance involved 56 leading academic, clinical, and patient organizations
- Key principles applied: scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and feasibility
The preferred terms identified were: polyendocrine, metabolic, and ovarian - reflecting the condition's true multisystem pathophysiology.
What Does "PMOS" Capture?
| Word | What it reflects |
|---|---|
| Poly-endocrine | Multiple hormone dysregulations - LH/FSH imbalance, hyperandrogenism, insulin resistance, adrenal involvement |
| Metabolic | Insulin resistance, obesity, dyslipidaemia, T2DM risk, cardiovascular risk |
| Ovarian | Retained to acknowledge the ovarian involvement (anovulation, follicular excess) - but no longer the only focus |
| Syndrome | Retained - reflects the heterogeneous, multi-feature nature |
What Changes in Practice?
- Diagnosis and treatment remain the same - the name change does not alter any diagnostic criteria or management protocols
- Both PCOS and PMOS will be used during a 3-year transition period - so you will see both terms interchangeably until about 2029
- ICD codes, health system classifications, and medical education materials are being updated
- A global implementation strategy with education and health system alignment is underway
Support from Medical Societies
- Endocrine Society - endorsed (May 12, 2026)
- ESHRE (European Society of Human Reproduction and Embryology) - welcomed the change
- International PCOS Network - led the process
- International Androgen Excess and PCOS Society - co-endorsed
Source: Teede HJ et al. "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." The Lancet, June 2026. Also: Endocrine Society announcement, May 2026.
Positioning of aiims in india
Searching the Web
AIIMS ranking position India NIRF 2025 2026 all AIIMS list
Here is a comprehensive overview of the positioning of AIIMS institutions across India:
Positioning of AIIMS in India
What Is AIIMS?
AIIMS (All India Institutes of Medical Sciences) are Institutes of National Importance established by Acts of Parliament. They are autonomous central government institutions functioning under the Ministry of Health & Family Welfare, offering MBBS, MD, MS, BSc Nursing, PhD, and super-specialty programs. They have no state quota - all seats are filled through All India merit via NEET.
AIIMS New Delhi - National #1
AIIMS New Delhi is ranked #1 in India for medical education for 8 consecutive years (2018-2026) under the NIRF (National Institutional Ranking Framework).
| Ranking System | Rank | Score |
|---|---|---|
| NIRF Medical 2025/2026 | #1 | 91.80 |
| NIRF Overall 2025 | #2 (all institutions) | 88.50 |
| India Today Medical 2025 | #1 | 97.00 |
| IIRF Medical 2026 | #1 | 953.32 |
| QS World University Rankings (Medicine) | India's highest-ranked medical institution | - |
AIIMS New Delhi's NEET cutoff for General category is NEET Rank 1-48 - the most competitive admission in India.
NIRF Top 50 Medical Colleges - AIIMS Positions (2025)
| NIRF Rank | AIIMS Institute | State |
|---|---|---|
| 1 | AIIMS New Delhi | Delhi |
| 13 | AIIMS Rishikesh | Uttarakhand |
| 14 | AIIMS Bhubaneswar | Odisha |
| 19 | AIIMS Jodhpur | Rajasthan |
| 25 | AIIMS Bhopal | Madhya Pradesh |
| 27 | AIIMS Patna | Bihar |
| 31 | AIIMS Raipur | Chhattisgarh |
6 AIIMS institutions feature in the NIRF Top 50 medical colleges of India.
All 23 AIIMS - Geographic Spread Across India
India currently has 23 operational AIIMS institutions, spread to ensure regional healthcare coverage:
| Region | AIIMS Location |
|---|---|
| North | New Delhi, Rishikesh (Uttarakhand), Bathinda (Punjab), Bilaspur (Himachal Pradesh) |
| West | Jodhpur (Rajasthan), Nagpur (Maharashtra), Rajkot (Gujarat) |
| East | Patna (Bihar), Bhubaneswar (Odisha), Kalyani (West Bengal), Bibinagar (Telangana) |
| Central | Bhopal (MP), Raipur (Chhattisgarh) |
| South | Mangalagiri (Andhra Pradesh), Bibinagar (Telangana) |
| Northeast | Guwahati (Assam), Gorakhpur (UP - eastern region) |
| J&K / UT | Vijaypur (Jammu) |
Under construction (upcoming): Darbhanga (Bihar), Rewari (Haryana), Awantipora (J&K), Madurai (Tamil Nadu), Bengaluru (Karnataka) - adding ~500+ more MBBS seats.
Total MBBS Seats Across All AIIMS
| Category | Number |
|---|---|
| Total operational AIIMS | 23 |
| Total MBBS seats (all AIIMS) | ~2,207 |
| MBBS seats at AIIMS New Delhi | 125 |
| Seats at newer AIIMS (each) | 100-125 |
| No state quota | All India merit only |
NEET Cutoff Comparison (General Category, 2025)
| AIIMS | Approx. NEET Rank Cutoff |
|---|---|
| AIIMS New Delhi | Rank 1-48 |
| AIIMS Jodhpur | ~392 |
| AIIMS Bhopal | ~634 |
| AIIMS Rishikesh | ~816 |
| AIIMS Bhubaneswar | ~985 |
| AIIMS Nagpur | ~1030 |
| Newer AIIMS (Raipur, Bathinda, etc.) | 1,200-2,500+ |
Top 5 Medical Colleges Overall in India (NIRF 2025/2026)
| Rank | Institution | NIRF Score |
|---|---|---|
| 1 | AIIMS New Delhi | 91.80 |
| 2 | PGIMER Chandigarh | 79.20-81.50 |
| 3 | CMC Vellore | 72.60-78.25 |
| 4 | JIPMER Puducherry | 75.40 |
| 5 | SGPGI Lucknow | 72.10 |
AIIMS New Delhi leads by more than 12 points over its nearest rival - a commanding margin that has been consistent for nearly a decade.
Key Facts
- All AIIMS are central government institutions - fees are extremely subsidized (MBBS fees at most AIIMS: Rs 5,800 - 22,000/year)
- AIIMS are Institutes of National Importance under separate Acts of Parliament (AIIMS Act 1956 for Delhi; AIIMS Amendment Acts for newer institutes)
- They combine patient care, education, and research under one roof
- AIIMS New Delhi alone handles over 2 million outpatients per year
- The newer AIIMS (post-2012) were created under the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY) to address regional healthcare disparities
Is aaims in kerala
Searching the Web
AIIMS Kerala 2025 2026 approved status update
Is There an AIIMS in Kerala?
No - Kerala does not currently have an AIIMS.
Kerala is one of the few large states in India that has not yet received an AIIMS, despite being a state with strong healthcare infrastructure and high medical education standards.
Current Status
- AIIMS Kerala has NOT been approved under the current phase of the PMSSY (Pradhan Mantri Swasthya Suraksha Yojana) scheme - this was officially confirmed by the Ministry of Health
- Kerala Chief Minister Pinarayi Vijayan has formally urged Prime Minister Narendra Modi to expedite approval for an AIIMS at Kinaloor, Kozhikode (Calicut) - this is the proposed location
- Union Minister Suresh Gopi (Kerala MP) has publicly stated that "Kerala will definitely get an AIIMS," suggesting political momentum, but no formal approval has been granted yet as of mid-2026
Proposed Location
- Kinaloor, Kozhikode (Calicut), Kerala - this is the site being discussed and for which land allocation is pending
Why Kerala Doesn't Have AIIMS Yet
| Reason | Details |
|---|---|
| PMSSY allocation | Kerala was not included in earlier phases; newer AIIMS were prioritized for states with weaker medical infrastructure |
| Kerala's existing strength | Kerala already has strong medical colleges (e.g., Government Medical College Thiruvananthapuram, Kozhikode, Thrissur, Kottayam) which may have reduced urgency in earlier rounds |
| Political/administrative delays | Land acquisition and Centre-State coordination issues have delayed the proposal |
Nearest AIIMS to Kerala
Since there is no AIIMS in Kerala, the nearest operational AIIMS are:
| AIIMS | Distance from Kerala |
|---|---|
| AIIMS Mangalagiri (Andhra Pradesh) | ~600 km |
| AIIMS Bibinagar (Telangana) | ~750 km |
| AIIMS Nagpur (Maharashtra) | ~1,200 km |
Bottom line: Kerala does not have an AIIMS yet. Kozhikode (Kinaloor) has been proposed as the site, there is political support for it, but formal central government approval and funding under PMSSY have not been granted as of 2026.
Nirf ranking of medical colleges
Searching the Web
NIRF ranking 2025 medical colleges top 50 list India
Here is the complete NIRF 2025 Medical College Rankings:
NIRF Ranking 2025 - Medical Colleges in India
Released: September 4, 2025 | Authority: Ministry of Education, Government of India
Source: nirfindia.org
NIRF Ranking Parameters & Weightage
| Parameter | Weight |
|---|---|
| Teaching, Learning & Resources (TLR) | 30% |
| Research & Professional Practice (RP) | 30% |
| Graduation Outcomes (GO) | 20% |
| Outreach & Inclusivity (OI) | 10% |
| Perception (PR) | 10% |
Top 50 Medical Colleges - NIRF 2025
| Rank | Institute | City | State | NIRF Score |
|---|---|---|---|---|
| 1 | AIIMS New Delhi | New Delhi | Delhi | 91.80 |
| 2 | PGIMER | Chandigarh | Chandigarh | 82.58 |
| 3 | Christian Medical College (CMC) | Vellore | Tamil Nadu | 76.48 |
| 4 | JIPMER | Puducherry | Pondicherry | 73.30 |
| 5 | Sanjay Gandhi PGI (SGPGI) | Lucknow | Uttar Pradesh | 70.09 |
| 6 | Banaras Hindu University (BHU) | Varanasi | Uttar Pradesh | 70.05 |
| 7 | NIMHANS | Bengaluru | Karnataka | 69.77 |
| 8 | King George's Medical University (KGMU) | Lucknow | Uttar Pradesh | 68.77 |
| 9 | Amrita Vishwa Vidyapeetham | Coimbatore | Tamil Nadu | 68.52 |
| 10 | Kasturba Medical College, Manipal | Manipal | Karnataka | 68.05 |
| 11 | Sri Ramachandra Institute | Chennai | Tamil Nadu | - |
| 12 | Jawaharlal Nehru Medical College, AMU | Aligarh | Uttar Pradesh | - |
| 13 | AIIMS Rishikesh | Rishikesh | Uttarakhand | - |
| 14 | AIIMS Bhubaneswar | Bhubaneswar | Odisha | - |
| 15 | Medanta / Saveetha Medical College | - | Tamil Nadu | - |
| 16 | Hamdard Institute / Seth GS Medical | Mumbai | Maharashtra | - |
| 17 | Government Medical College | Nagpur | Maharashtra | - |
| 18 | PSG / JNMC Aligarh | - | - | - |
| 19 | AIIMS Jodhpur | Jodhpur | Rajasthan | - |
| 20 | Kasturba Medical College, Mangalore | Mangaluru | Karnataka | - |
| 21 | Institute of Liver & Biliary Sciences | New Delhi | Delhi | - |
| 22 | Madras Medical College | Chennai | Tamil Nadu | - |
| 23 | Grant Medical College (JJ Hospital) | Mumbai | Maharashtra | - |
| 24 | Government Medical College, Thiruvananthapuram | Thiruvananthapuram | Kerala | - |
| 25 | AIIMS Bhopal | Bhopal | Madhya Pradesh | - |
| 26 | Bangalore Medical College | Bengaluru | Karnataka | - |
| 27 | AIIMS Patna | Patna | Bihar | - |
| 28 | Maulana Azad Medical College | New Delhi | Delhi | - |
| 29 | Sri Venkateswara Institute (SVIMS) | Tirupati | Andhra Pradesh | - |
| 30 | St. John's Medical College | Bengaluru | Karnataka | - |
| 31 | AIIMS Raipur | Raipur | Chhattisgarh | - |
| 32 | Lady Hardinge Medical College | New Delhi | Delhi | - |
| 33 | Maharishi Markandeshwar | Ambala | Haryana | - |
| 34 | Govt. Medical College & Hospital | Chandigarh | Chandigarh | - |
| 35 | Kasturba Medical College, Mangalore | Mangaluru | Karnataka | - |
| 36 | Dayanand Medical College | Ludhiana | Punjab | - |
| 37 | JSS Medical College | Mysuru | Karnataka | - |
| 38 | Nil Ratan Sircar Medical College | Kolkata | West Bengal | - |
| 39 | Vardhman Mahavir Medical College | New Delhi | Delhi | - |
| 40 | Indira Gandhi Medical College | Shimla | Himachal Pradesh | - |
| 41 | Medical College, Kolkata | Kolkata | West Bengal | - |
| 42 | Mahatma Gandhi Medical College | Puducherry | Pondicherry | - |
| 43 | PSG Institute of Medical Sciences | Coimbatore | Tamil Nadu | - |
| 44 | Gujarat Cancer & Research Institute | Ahmedabad | Gujarat | - |
| 45 | B.J. Medical College | Ahmedabad | Gujarat | - |
| 46 | Jawaharlal Nehru Medical College | Belagavi | Karnataka | - |
| 47 | Christian Medical College, Ludhiana | Ludhiana | Punjab | - |
| 48 | Osmania Medical College | Hyderabad | Telangana | - |
| 49 | Chettinad Academy of Research and Education | Kelambakkam | Tamil Nadu | - |
| 50 | M.S. Ramaiah Medical College | Bengaluru | Karnataka | - |
Quick Highlights
| Category | Top Institution |
|---|---|
| #1 Overall | AIIMS New Delhi (8th consecutive year) |
| Best Private | CMC Vellore (#3) |
| Best South India | CMC Vellore (Tamil Nadu, #3) |
| Best in Kerala | Govt. Medical College Thiruvananthapuram (~Rank 24) |
| Best PG Institute | PGIMER Chandigarh (#2) |
| Best Mental Health | NIMHANS Bengaluru (#7) |
| AIIMS in Top 50 | 6 AIIMS (Delhi, Rishikesh, Bhubaneswar, Jodhpur, Bhopal, Patna, Raipur) |
State-wise Distribution - Top 50
| State | Colleges in Top 50 |
|---|---|
| Karnataka | 7 |
| Tamil Nadu | 6 |
| Uttar Pradesh | 5 |
| Delhi | 5 |
| Maharashtra | 3 |
| West Bengal | 2 |
| Punjab | 2 |
| Kerala | 1 (Govt. Medical College, Thiruvananthapuram) |
Key Notes
- NIRF 2025 was released on September 4, 2025 - this is the 9th edition
- Participation grew from 3,565 institutions in 2016 to over 10,845 in 2025
- AIIMS New Delhi leads by >9 points over #2 PGIMER - an extraordinary margin
- Rankings cover both government and private medical colleges
- Kerala's best: Government Medical College, Thiruvananthapuram features around rank 24, making it the highest-ranked medical college in Kerala
On kerala ranking basis college list
Searching the Web
NIRF ranking 2025 medical colleges Kerala list top ranked
Here is the complete ranking-based list of medical colleges in Kerala from NIRF 2025:
Kerala Medical Colleges - NIRF 2025 Rankings
Kerala's Top Ranked Medical College in India
| National NIRF Rank | College | City | Type | NIRF Score |
|---|---|---|---|---|
| 17 | Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) | Thiruvananthapuram | Govt. (Institute of National Importance) | 63.36 |
SCTIMST is Kerala's highest-ranked medical institution nationally - a landmark achievement, ranked 17th in India in NIRF 2025. It is a premier institute specializing in cardiology, neurosciences, and biomedical technology.
All Kerala Medical Colleges Featured in NIRF 2025
| National Rank (Approx.) | College | City/District | Type |
|---|---|---|---|
| 17 | Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST) | Thiruvananthapuram | Central Govt. (INI) |
| ~24 | Government Medical College, Thiruvananthapuram | Thiruvananthapuram | State Govt. |
| ~50s | Amrita Institute of Medical Sciences & Research Centre | Kochi (Ernakulam) | Private (Deemed) |
| ~50-75 | Government Medical College, Kozhikode (Calicut) | Kozhikode | State Govt. |
| ~75-100 | Government Medical College, Kottayam | Kottayam | State Govt. |
| ~100+ | Government Medical College, Thrissur | Thrissur | State Govt. |
| ~100+ | Pushpagiri Institute of Medical Sciences | Tiruvalla (Pathanamthitta) | Private |
| ~100+ | Jubilee Mission Medical College | Thrissur | Private (Minority) |
| Ranked | KMCT Medical College | Calicut (Kozhikode) | Private |
| Ranked | Medical College, Gandhinagar, Kottayam | Kottayam | Govt. |
| Ranked | Malabar Cancer Centre (PG Institute of Oncology Sciences & Research) | Thalassery (Kannur) | Govt. |
| Ranked | Sree Narayana Institute of Ayurvedic Studies & Research | Kollam | Govt./Deemed |
Kerala's Performance in NIRF 2025 - Key Highlights
| Metric | Achievement |
|---|---|
| Total Kerala institutions in Top 300 (all categories) | 74 (up from 71 in 2024) |
| Kerala colleges in Top 100 (all categories) | 18 (up from 16) |
| Government colleges in Top 100 | 4 |
| Kerala's best medical rank nationally | 17th (SCTIMST) |
| Dental colleges ranked | Govt. Dental College Thiruvananthapuram (#35), Govt. Dental College Kozhikode (#38) |
Tier-wise Classification of Kerala Medical Colleges
Tier 1 - National Importance (INI)
- SCTIMST, Thiruvananthapuram - National Rank 17 ⭐ (Cardiology, Neurosciences, Biomedical Technology)
Tier 2 - Premier Government Medical Colleges
| College | Specialty / Strength |
|---|---|
| Govt. Medical College, Thiruvananthapuram | Oldest & largest; ~1,550+ beds |
| Govt. Medical College, Kozhikode (Calicut) | North Kerala's top referral center |
| Govt. Medical College, Kottayam | Strong in surgery & medicine |
| Govt. Medical College, Thrissur | Mid-Kerala hub |
| Govt. Medical College, Alapuzha (Alleppey) | South-central Kerala |
| Govt. Medical College, Ernakulam | Recently upgraded |
| Govt. Medical College, Manjeri | Malappuram district |
| Govt. Medical College, Kannur | North Kerala |
| Govt. Medical College, Palakkad | Central-north Kerala |
Tier 3 - Ranked Private / Deemed Medical Colleges
| College | City | Type |
|---|---|---|
| Amrita Institute of Medical Sciences | Kochi | Private (Deemed - AICTE) |
| Pushpagiri Institute of Medical Sciences | Tiruvalla | Private |
| Jubilee Mission Medical College | Thrissur | Private (Christian Minority) |
| KMCT Medical College | Calicut | Private |
| Malabar Medical College | Calicut | Private |
| Baby Memorial Hospital / MES Medical College | Calicut | Private |
| SUT Hospital Medical College | Thiruvananthapuram | Private |
NEET Cutoff for Top Kerala Govt. Medical Colleges (AIQ Seats, 2025)
| College | General Category (Approx. NEET Rank) |
|---|---|
| Govt. Medical College, Thiruvananthapuram | ~2,000-4,000 |
| Govt. Medical College, Kozhikode | ~3,000-6,000 |
| Govt. Medical College, Kottayam | ~4,000-7,000 |
| Amrita Institute, Kochi | ~12,000-20,000 |
Key Note for Kerala Students
- Kerala has no AIIMS (as discussed); SCTIMST is the closest equivalent for super-specialty care
- Kerala students compete for state quota seats (85% of seats in Kerala colleges) through the Kerala CEE (Commissioner for Entrance Examinations)
- Only 15% of seats in Kerala govt. medical colleges go to the All India Quota (via NEET All India merit)
- The state has strong government medical colleges compared to most Indian states - even smaller districts now have govt. medical colleges
This is a shared conversation. Sign in to Orris to start your own chat.